Announcements Trials

Browse Landscape

Phase

Phase 2 2 Phase 1 2 Phase NA 1 Phase 3 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1 Endocrine 1

Conditions

Neuroendocrine Tumors 1

Interventions

Exercise 439 Blood Specimen Collection 333 Standard of Care 321 Magnetic Resonance Spectroscopy 259 Radiotherapy 255 Surveys and Questionnaires 245 Radiosurgery 245 Educational Status 230 Methods 229 Early Intervention, Educational 218 Practice Guidelines as Topic 146 Interviews as Topic 146 Biopsy 146 Surgical Procedures, Operative 135 Drug Therapy 133 Control Groups 128 Acupuncture Therapy 124 Therapeutics 110 Cyclophosphamide 103 Palliative Care 101 Counseling 101 Resistance Training 95 Saline Solution 90 Cisplatin 90 Magnetic Resonance Imaging 89 Radiofrequency Ablation 86 Specimen Handling 79 Radiotherapy, Intensity-Modulated 79 Colonoscopy 79 Cognitive Behavioral Therapy 72

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase NA × copper dotatate CU-64 × Clear all

NCT02125474 2019-11-14

Efficacy of 177-Lu-DOTA 0, Tyr 3 Octreotate

Instituto Nacional de Cancerologia, Columbia

Phase NA Completed

Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon ⚡